PEPCLUB.me

Metabolic HealthWeight ManagementCardiovascular HealthBody CompositionArticleFree

Retatrutide

10mg Vial

20mg Vial

30mg Vial

40mg Vial

60mg Vial

2 July 2026Updated 18 September 2026

Retatrutide

Overview Research16 Mechanism Protocols Safety

Discussions

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 12 known interactions

Synergistic(2)Compatible(3)Monitor(4)Avoid(3)

Generally well-tolerated alongside this peptide

Statins (atorvastatin, rosuvastatin)

No expected pharmacokinetic or pharmacodynamic interactions; coadministration is generally safe and requires routine lipid monitoring only.

ACE inhibitors / ARBs (lisinopril, losartan)

Antihypertensive therapy is typically compatible with retatrutide and does not require dose alteration beyond routine blood‑pressure monitoring.

Proton pump inhibitors (omeprazole)

No clinically significant interaction expected; gastric pH changes from PPI therapy do not meaningfully alter peptide activity.

All interaction categories

Synergistic (2)

SGLT2 inhibitors (empagliflozin, dapagliflozin): Complementary mechanisms produce additive glycaemic lowering and weight-loss effects when combined with retatrutide, potentially improving cardiometabolic outcomes.
Metformin: Complementary glucose‑lowering and insulin-sensitising effects enhance overall glycaemic control and weight management without major pharmacokinetic interactions.

Compatible (3)

Statins (atorvastatin, rosuvastatin): No expected pharmacokinetic or pharmacodynamic interactions; coadministration is generally safe and requires routine lipid monitoring only.
ACE inhibitors / ARBs (lisinopril, losartan): Antihypertensive therapy is typically compatible with retatrutide and does not require dose alteration beyond routine blood‑pressure monitoring.
Proton pump inhibitors (omeprazole): No clinically significant interaction expected; gastric pH changes from PPI therapy do not meaningfully alter peptide activity.

Monitor (4)

Insulin (basal/bolus preparations): Retatrutide can enhance glucose lowering and increase hypoglycaemia risk, so blood glucose should be closely monitored and insulin doses adjusted as needed.
Sulfonylureas (glimepiride, gliclazide): Concomitant use raises hypoglycaemia risk due to additive glucose‑lowering effects and requires closer glycaemic monitoring and possible dose reduction.
Warfarin: Weight change, altered oral intake or gastrointestinal effects may affect INR; monitor anticoagulation (INR) when initiating or changing retatrutide therapy.
Oral combined hormonal contraceptives: Delayed gastric emptying may alter absorption of oral contraceptives in some patients, so monitor for reduced contraceptive efficacy and consider counselling or alternatives if concerns arise.

Avoid (3)

Other incretin-based therapies (GLP‑1 receptor agonists, e.g., semaglutide; dual agonists e.g., tirzepatide): Overlapping incretin/glucagon pharmacology increases the likelihood of severe gastrointestinal adverse effects and hypoglycaemia and generally should not be combined without specialist oversight.
Levothyroxine: Delayed gastric emptying may reduce or variably delay levothyroxine absorption, so spacing doses and monitoring thyroid function tests is advised when starting or stopping retatrutide.
Sympathomimetic agents (pseudoephedrine, amphetamine derivatives): Because retatrutide has glucagon receptor activity and can affect heart rate, combine with sympathomimetics cautiously due to potential additive cardiovascular stimulation.